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Marijuana is the most commonly used illicit drug in the United States (National Institute 
on drug Abuse [NIDA], 2018). Nationwide, 6% of pregnant women report marijuana use (Crume 
et al., 2018) with 5% of mothers continuing their marijuana use while breastfeeding (Crume et 
al., 2018). Professional guidelines established by the Academy of Breastfeeding Medicine 
(ABM)(Reese-Stremtan & Marinelli, 2015), the American Academy of Pediatrics 
(AAP)(American Academy of Pediatrics [AAP], 2012 and 2018), and the American College of 
Obstetricians and Gynecologists (ACOG)(ACOG, 2017) all agree that breastfeeding mothers 
should be screened for marijuana use and counseled based on existing evidence.  
In the absence of knowing the status of the breastfeeding mother’s marijuana use, the 
opportunity to provide evidence-based counseling regarding substance use and its impact on both 
the mother and nursing infant’s health and milk supply is missed. 
The purpose of this quality improvement project was to identify the degree to which 
breastfeeding mothers were using marijuana and to document evidence-based counseling on 
effects during breastfeeding. The project was accomplished by (1) training pediatric healthcare 
providers in evidence-based recommendations to breastfeeding mothers regarding marijuana use 
and (2) establishing an electronic system to facilitate provider counseling of evidence-based 
recommendations.  
Primary findings were that breastfeeding mothers were not routinely screened at the two 
week well infant visit about maternal marijuana use and evidence-based counseling was not 
standardized. After provider training was delivered and electronic –associated reminder and  
evidence-based counseling was embedded into the health record, the percentage of breastfeeding 
mothers being screened about marijuana use increased by approximately 50%.  Additionally, 
 MARIJUANA AND BREASTFEEDING  
 
7 
women who acknowledged marijuana use while nursing were given standard, evidence-based 
counseling regarding the effects of marijuana use while breastfeeding. It was concluded that 
provider education and ease of standardized documentation of provider counseling increased 
both maternal inquiry into marijuana use and provider counseling and documentation of 
evidence-based counseling. 
  




Section One: Nature of the Problem 
Introduction to the Problem 
 Marijuana is the most commonly used illicit drug in the United Sates (National Institute 
on Drug Abuse [NIDA], 2018). It is made from dried parts of the cannabis sativa or cannabis 
indica plant. Marijuana (cannabis), classified as a schedule I illegal substance, has become 
legalized in several states. A schedule I drug is defined as a “drug, substance or chemical with no 
currently accepted medical use and a high potential for abuse”  (United States Drug Enforcement 
Administration [DEA], 2018) There are two types of marijuana use designations: medical and 
recreational.  Medical marijuana is defined as “using the whole unprocessed marijuana plant or 
its basic extracts to treat a disease or symptom” (National Institute on Drug Abuse [NIDA], 
2018). The primary use of cannabis in the United States is recreational (89.5 percent of adult 
users) (Schauer, King, Bunnell, Promoff, & McAfee, 2016). Thirty states and the District of 
Columbia have laws legalizing some form of marijuana use (“State marijuana laws in 2018,” 
2018). Ten states (Alaska, California, Colorado, Maine, Massachusetts, Michigan, Nevada, 
Oregon, Vermont and Washington) and the District of Columbia have legalized recreational 
adult-use (“State marijuana laws in 2018,” 2018).  
 Nationwide, 6% of pregnant women report marijuana use (Crume et al., 2018)  with 5% 
of mothers continuing their marijuana use while breastfeeding (Crume et al., 2018). In 2014, 
according to the Centers for Disease Control (CDC), 79.2% of U.S. mothers initiated 
breastfeeding. Alaska exceeded the national initiation rate at 87.3% (Center for Disease Control, 
2014). Alaskan statistics mirror the national average with 6% of pregnant women reporting 
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marijuana use during pregnancy but an increased 8% of nursing mothers reporting marijuana use 
during breastfeeding (Alaska Department of Health and Human Services, 2015) . 
 The literature is limited and contradictory regarding recreational marijuana use during 
breastfeeding, making it challenging to advise breastfeeding mothers about the impact of their 
marijuana use on themselves and their infant. It is unlikely that new research will be generated in 
this field due to ethical considerations and marijuana’s schedule classification, thus limiting the 
body of evidence needed to inform decision making in this population. 
 The U.S Drug Enforcement Administration (DEA) controls substances with a high rate of 
abuse such as marijuana. Such drugs and their potential negative effects on communities are 
primary reasons why the DEA controls these drugs. On the other hand, if studies are not able to 
be conducted on schedule I drugs, researchers will be unable to discover the potential benefits 
that substances like marijuana may possess. This leads to limited studies lacking necessary rigor 
to review related to the topic.  
 When counseling breastfeeding mothers about infant effects of marijuana use during 
breastfeeding, a key question is whether the active substance or its metabolites will transfer 
through maternal breastmilk and affect the nursing infant. Regarding marijuana and its active 
metabolite, -9-tetrahydrocannabinol (THC), the length and route of exposure, quantity and type 
of user (occasional or chronic) all impact how much THC is present in maternal breastmilk.  
 Professional guidelines based on existing animal and human research have been 
established by the Academy of Breastfeeding Medicine (ABM)(Reece-Stremtan & Marinelli, 
2015) , the American Academy of Pediatrics( AAP), (American Academy of Pediatrics [AAP] , 
2012) and the American College of Obstetricians and Gynecologists (ACOG), (ACOG, 2017)  as 
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well as the Alaska Department of Health and Human Services (DHHS) (Butler, 2017). Though 
their recommendations vary, all agree that breastfeeding mothers should be screened for 
marijuana use and counseled based on existing evidence. The gap identified between the 
professional recommendations and current provider practice is evident when documentation is 
reviewed. The recommended surveillance of breastfeeding mothers regarding their potential 
marijuana use and subsequent documentation of evidence-based counseling is the basis of this 
DNP project.   
Purpose/Objective of the Quality Improvement Project 
 A quality improvement project seeks to improve the processes or outcomes of the care 
being delivered (Mazurek Melnyk & Fineout-Overholt, 2015) The purpose of this quality 
improvement project is to identify the degree to which breastfeeding mothers are using 
marijuana and to document evidence-based counseling on effects during breastfeeding.  We will 
accomplish this by (1) training pediatric health care providers in evidence-based 
recommendations to breastfeeding mothers regarding marijuana use and (2) establish an 
electronic system to facilitate provider counseling of evidence-based recommendations regarding 
marijuana use to breastfeeding mothers. We anticipate the outcome to be increased identification 
of breastfeeding mothers who use marijuana and improved documentation of evidence-based 
counseling regarding the effects of marijuana on the breastfeeding dyad.  
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Section Two: Review of Literature 
Clinical Practice Problem Statement 
 Among pediatric healthcare providers who counsel breastfeeding mothers (P), how does 
standardized evidence-based provider training regarding counseling mothers about marijuana use 
during breastfeeding (I) compared to no standardized training (C) affect documentation of 
maternal education about marijuana use during breastfeeding (O) over a six-month period (T)? 
 
Evaluation of Literature 
 Few high quality recent quantitative studies on marijuana use during breastfeeding were 
available for review due to marijuana’s schedule 1 classification. The database search was 
extended to all human and animal studies dating back to the 1970’s in order to provide a 
comprehensive review of the literature. It was determined that research publication date would 
not be restricted due to the limited number of studies available on the subject. Search engines 
included PubMed, CINAHL and Cochrane Review. Terms utilized in the search included 
marijuana, cannabis, THC, breastfeeding, perinatal, and lactation. A total of 272 articles were 
reviewed. Articles were excluded for lack of significant focus on the subject, information that 
overlapped with primary studies and duplicate articles. A total of 41were included in the critical 
analysis evaluation synthesis. These included, 5 randomized control studies, 3 experimental 
studies, 3 systematic reviews, 9 quasi-experimental studies, 3 non-experimental studies, 1 
protocol statement, 3 policy statements, 1 expert opinion, 2 cross sectional studies, 1 qualitative 
study and 10 literature reviews. Articles were categorized into four main areas of focus. These 
were THC pharmacokinetics, marijuana effects on infants, maternal marijuana effects and 
professional guidelines/opinions.  All articles were critically reviewed using critical appraisal 
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principles as described by Melnyk & Fineout-Overholt  (2017, p. 87-135). Comprehensive 
evaluation and synthesis tables of all literature reviewed are found in Tables 1 and 2. 
Overview of Literature 
 Tetrahydrocannabinol Pharmacokinetics 
Existing research on marijuana focuses on THC, the principle psychoactive component. 
THC accumulation is dependent on the user’s frequency of exposure (U S National Library of 
Medicine, 2018).  THC is metabolized in the liver and has a half-life of 20-36 hours but may be 
as long as four days in chronic users because of its ability to be stored in body fat (Bennett, 
1996). THC accumulates in fat at a rate ten times greater than any other tissue and can persist for 
up to two weeks (Kreuz & Axelrod, 1973), contributing to the THC long half- life. Half -life is 
defined as the amount of time it takes one half of a drug’s dose to be excreted from the body. A 
recent study by Bertrand et al. (2018) found that delta-9-THC was measurable in breastmilk an 
average of 6 days after maternal marijuana use.  The urinary half-life of THC’s metabolite 
(THCCOOH) was calculated at 4 to 12 days for infrequent users and 17 to 27 days for frequent 
users (Smith-Kielland, Skuterud, & Morland, 1999). The route of THC exposure also affects 
when THC peaks in one’s blood. Smoking marijuana causes a peak serum concentration of THC 
in one to two hours whereas oral consumption yields peak levels in two to four hours (Hollister 
et al., 1981).  
Focusing on THC secretion into breastmilk, frequency of use remains a factor. Animal 
secretion rates into breastmilk were slower in chronic users than with occasional users (Chao et 
al., 1976). Human studies by Perez-Reyes & Wall (1982) found that there was an 8-fold increase 
in THC accumulation in breastmilk with increased frequency of use (Perez-Reyes & Wall, 
1982). They calculated that 0.8% of the weight-adjusted maternal intake of one marijuana 
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cigarette would be transferred to the infant in one nursing (0.8% of its mother’s dose/kg). This 
ratio was also found to be valid in another human study by Liston (1998). 
THC transfer into mammal milk has been consistently documented in several human 
studies and is generally tested by liquid chromatography tandem mass spectrometry (Marchei et 
al., 2011). D’apolito (2013) outlined the factors that affected drug transfer into breastmilk. Three 
key areas are molecular weight, acid/base balance or pKa and lipid solubility. The lower the 
molecular weight of a drug, the more readily it transfers into breastmilk. Drugs that are more 
basic become highly ionized and will become trapped in breast milk and are found in higher 
concentrations in breastmilk than maternal plasma.  When a drug is lipid soluble, if plasma 
concentrations of the drug are low, the drug becomes trapped in the fat molecule (Hale & Rowe, 
2017, p. el164-172). Marijuana has a relatively low molecular weight of 314.46 g/mol, is more 
basic with a pKa (acid-base dissociation constant) of 10.6 and is lipid soluble (D'apolito, 2013). 
One additional breastmilk factor that affects drug transfer is the composition of foremilk and 
hindmilk. Foremilk (milk produced in the first 3 minutes of feeding or pumping) has less fat than 
hindmilk (the remainder of milk produced during a feeding or pumping session). Understanding 
that marijuana is fat soluble, increased amounts can be found in hindmilk (Gardiner, 2001).   
This is significant when looking at the feeding pattern of the infant and how long they are at the 
breast (D'apolito, 2013).  
 Effects of Marijuana Exposure on Infants 
When one looks at specific effects of cannabis on offspring, several issues may confound 
findings. In human studies, it is often difficult to separate prenatal and postnatal exposures as 
well as environmental factors on infant outcomes from maternal marijuana use. Incorporating 
animal studies allows for better prenatal control but does not consider environmental factors 
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(Campolongo, Trezza, Ratano, Palmery, & Cuomo, 2011). Additionally, different animal species 
may metabolize marijuana differently possibly rendering animal studies nontransferable to 
human subjects. With these two key points in mind, the literature was reviewed for infant effects 
of maternal marijuana use focusing on marijuana exposure during lactation though several 
studies also reported prenatal exposure.   
The endocannabinoid system is critical in neurotransmission and is the primary target of 
THC (Jutras-Aswad, DiNieri, Harkany, & Hurd, 2009). This system and its cannabinoid 
receptors are functional around nineteen weeks gestation in humans (Campolongo et al., 2011).  
This illustrates why prenatal cannabis exposure may be a factor when looking at infant effects 
but is difficult to control in human studies. 
Perinatal (pre and post-natal) exposure to cannabis was associated with long term 
behavioral and neuroendocrine changes in adult rats (Moreno, Escuredo, Munoz, Rodriguez de 
Fonseca, & Navarro, 2005; Trezza et al., 2008). Newsom and Kelly (2008) also found that 
perinatal THC exposure in male rats makes them more susceptible to anxious behavior and 
altered social functioning (Newsom & Kelly, 2008). 
Human studies on perinatal cannabis exposure during lactation are contradictory.  Tennes 
et al. (1985) focused on the perinatal spectrum and concluded that there were no significant 
differences in growth and development of infants at one year of age and that marijuana use did 
not interfere with lactation (Tennes et al., 1985). A landmark study by Astley & Little (1990) 
concluded that infants who were exposed to THC in their first and third month of life 
experienced motor development delays at one year of age but could not postulate any long-term 
infant effects due to the short study duration (Astley & Little, 1990).  The authors also reported 
no detectable mental developmental delays at one year of age.  
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THC exposure via maternal breastmilk may cause sedation, poor growth, reduced muscle 
tone and poor suckling in infants (Liston, 1998). Infants have also shown lethargy, less frequent 
feeding and shorter feeding times after THC exposure (Institute of Medicine, 1991). To 
summarize, prenatal use of THC targets the endocannabinoid system which is present at 19 
weeks gestation. It may cause behavioral and endocrine changes exhibited by offspring such as 
anxiety and altered social functioning. It may cause motor delays at 1 and 3 months of life but 
these changes do not seem to be sustained at one year of age. THC exposure may also cause 
infant sedation and lethargy, poor growth, reduced muscular tone, and overall decreased feeding 
initiation and duration.  
Maternal Effects of Marijuana 
  The secretion of milk by the mammary glands (lactogenesis) is triggered by the 
abrupt drop in the hormones progesterone and estrogen after birth. This causes the anterior 
pituitary gland to release large amounts of prolactin (D'apolito, 2013), prompting milk 
production. Oxytocin is also produced by the posterior pituitary in response to infant suckling 
(Tyrey & Murphy, 1988), contributing to milk ejection. Both prolactin and oxytocin secretion are 
affected by THC. Four animal studies have demonstrated that rats exposed to THC in maternal 
milk decreased both oxytocin and prolactin release in the mother (Tyrey & Murphy, 1988; 
(Vilela & Giusti-Paiva, 2014; Bromley, Rabii, Gordon, & Zimmerman, 1978; Asch, Smith, Siler-
Khodr, & Pauerstein, 1979). Three studies on humans have also demonstrated that THC 
suppresses prolactin levels in nursing mothers (Murphy, Munoz, Adrian, & Villanua, 1998; 
Mendelson, Ellingboe, & Mello, 1984; Ranganathan et al., 2009).  
 THC has also been shown to affect mothers’ care of their infants. Three rodent studies 
demonstrated that THC exposed mothers decreased their licking, retrieval and carrying of their 
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pups (Vilela & Giusti-Paiva, 2014) along with an overall decrease in maternal care of pups 
(Bromley et al., 1978) and decreased maternal nonsocial activities (Frischknecht, Sieber, & 
Waser, 1980). One additional study involving rhesus monkeys also demonstrated maternal 
depression and lethargy during nursing after THC exposure (Asch & Smith, 1986). Additionally, 
cannabis use with humans was shown to decrease breastfeeding initiation (Crume et al, 2018) as 
well as shorten breastfeeding duration (Ko, Farr, Tong, Creanga, & Callaghan, 2015). 
Recommendations for Marijuana Use While Breastfeeding 
  The recent increase in marijuana use and legalization in the US has prompted 
several literature reviews on the subject. Seven reviews were analyzed with publication dates 
from 2009 through 2018. Authors encouraged providers to counsel mothers to avoid marijuana 
use while breastfeeding but failed to provide guidance regarding its use (Merritt, Wilkinson, & 
Chervenak, 2016). Two reviews stated that breastfeeding is contraindicated with marijuana use 
(Garry et al., 2009;Metz & Stickrath, 2015). Findings from the 4 remaining literature reviews 
reflect a cautious stance but recommended counseling breastfeeding mothers who use marijuana 
(Hill & Reed, 2013; Jaques et al., 2014; Mourh & Rowe, 2017; Brown, Dakkak, & Seabrook, 
2018). Authors from all reviews identify the lack of rigorous human studies and confounding 
evidence as reasons for their lack of ability to make well-informed recommendations regarding 
marijuana use in lactation. Mourh & Rowe (2017 p. 594) state that the “final decision is 
ultimately up the individual woman”. 
The AAP (2012) issued a policy statement on breastfeeding and the use of human milk. It 
extols the benefits of breastfeeding to reduce respiratory tract infections as well as decreasing the 
incidence of otitis media, gastrointestinal infections, necrotizing enterocolitis, sudden infant 
death syndrome and allergies. It also credits breastfeeding with reducing the incidence of celiac 
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disease, inflammatory bowel disease, obesity, diabetes, childhood leukemia and lymphoma and 
improving intelligence scores. The AAP also supports feeding preterm infants breastmilk and 
lists the health benefits for the mother (decreased postpartum blood loss, increased child spacing, 
decreased postpartum depression and weight loss). Economic benefits of breastfeeding were 
highlighted and exclusive breastfeeding for the first six months of the infant’s life with continued 
breastfeeding for at least one year was recommended. The AAP states that there are a limited 
number of conditions where breastfeeding is contraindicated. These are infant glactosemia, 
mothers who are positive for human T-cell lymphtropic virus type I or II, untreated brucellosis, 
untreated tuberculosis or active herpes simplex lesions on the breast (though expressed 
breastmilk in this instance is recommended). Regarding HIV-positive mothers, if they are in the 
industrialized world, breastfeeding is not recommended but in developing countries, infant 
mortality is decreased if breastfeeding continues. Regarding “street drugs such as PCP, cocaine 
and cannabis”, the AAP (2012) states concern regarding the infant’s long-term neurobehavioral 
development and the stance that breastfeeding is contraindicated. The AAP cites the review 
article by Garry et al. (2009) specifically as the sole source for this recommendation. In an 
updated publication published in September of 2018, the AAP softened its stance, citing that 
present data is insufficient to assess the effects of marijuana exposure on breastfeeding infants 
and recommended that providers encourage mothers to breastfeed while “strongly encouraging 
that she abstain completely from using marijuana” while breastfeeding (AAP, 2018). Finally, the 
AAP strongly discourages the use of alcohol and maternal smoking while breastfeeding (AAP, 
2012) and specifically addressed passive marijuana smoke exposure in its 2018 update (AAP, 
2018). 
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In contrast, the ABM stated in its clinical protocol regarding breastfeeding and substance 
use that “breastfeeding mothers should be counseled to reduce or eliminate their use of 
marijuana” and “advised of the possible long-term neurobehavioral effects” (Reece-Stremtan & 
Marinelli, 2015 p. 138) .  The ABM advised caution basing recommendations solely on the 
legality of marijuana due to changing laws regarding marijuana use. They also cite 7 animal and 
human studies, all of which have been reviewed for this project, prior to issuing their cautionary 
use of marijuana while breastfeeding. The ABM specifically states that current studies are 
insufficient to recommend complete abstention from breastfeeding but urge caution while 
breastfeeding while using marijuana (Reece-Stremtan & Marinelli, 2015). 
The ACOG (2017) published a committee opinion that stated “insufficient evidence to 
evaluate the effects of marijuana use on infants during lactation and breastfeeding, and in the 
absence of such data, marijuana use is discouraged” (ACOG, 2017 p. e205). Specifically, the 
committee’s opinion on marijuana use during lactation cites the ABM article by Reece-Stremtan 
and Marinelli (2015). 
 In Alaska, the Department of Health and Human Services (DHHS) published a 
memorandum addressed to all healthcare providers citing the AAP, ABM and ACOG published 
guidelines and recommended to “continue to breastfeed while making every effort to reduce the 
amount of marijuana consumed, whether smoked, vaped or eaten” (Butler, 2017). The 
memorandum further recommended stopping marijuana use during pregnancy, protecting 
children from second-hand marijuana smoke as well as safely storing marijuana and edibles 
away from children. It also advised against driving a car with child passengers while under the 
influence of marijuana and to have a sober, unimpaired child care provider take care of children 
when a parent is impaired by any substance, including marijuana (Butler, 2017). Therefore, the 
 MARIJUANA AND BREASTFEEDING  
 
19 
consensus is to continue breastfeeding while mothers make a concerted effort to reduce their 
marijuana intake while nursing.   
Critical Appraisal of the Evidence 
 The most popular illicit drug in the United States is marijuana. Given its popularity and 
increasing legalization rates in the US, it is not unusual that healthcare providers are 
experiencing an increased prevalence of use among their patients. One unique population of 
healthcare consumer is the breastfeeding dyad. Healthcare providers caring for breastfeeding 
dyads have two patients to consider when counseling mothers, both mother and nursing infant. 
The research regarding marijuana use and its effects on the dyad is limited. In order to cast the 
widest net for review, animal studies were included when generating evidence-based 
recommendations. Limitations with the inclusion of animal studies stem from the difference in 
species and translation to human effects.  
To summarize, THC, the active metabolite in marijuana, transfers from maternal blood 
into breastmilk of mammals and can be measured in the breastfeeding infant (Asch &Smith, 
1986; Chao, Green, Forrest et al, 1976; Metz & Stickrath, 2015; Perez-Reyes & Wall, 1982). 
Amount of THC consumed, method of ingestion and chronicity of use all are contributing factors 
when evaluating how much THC the infant is ingesting. Here is where the consensus ends. Infant 
and maternal effects of THC are frequently contradictory. Infant effects from THC exposure can 
include decreased neuromotor development (Astley & Little, 1990; Metz & Stickrath, 2015; 
Moreno et al, 2005; Trezza et al, 2008) behavioral changes (Moreno et al, 2005; Newsom & 
Kelly, 2008) decreased growth and muscle tone and impaired social functioning. Maternally, 
THC has been shown to decrease secretion of oxytocin and prolactin (Asch &Smith, 1979; 
Mendelson, Ellingboe & Mello, 1984; Ranganatham et al, 2009; Tyrey & Murphy, 1988); 
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decrease breastfeeding initiation and duration (Crume, Julh, Brooks-Russell, Hall, Wymore & 
Borgelt, 2018), cause maternal depression (Ko, Tong, Bombard, Hayes, Davy & Perham-Hester, 
2018) and negatively affect maternal care of infants (Bromley, Rabii, Gordan & Zimmerman, 
1978; Frischknecht, Sieber, & Waser, 1980; Vilela & Giusti-Paiva, 2014). All of these facts, 
proven in one human or animal study, have also been challenged by other researchers (Tennes et 
al, 1985). Even the three reviewed professional organizations, the AAP, ABM, and ACOG, 
differ in their published recommendations regarding counseling of breastfeeding mothers who 
use marijuana. The one fact that these organizations agree upon is that these mothers should be 
counseled regarding marijuana use while breastfeeding (AAP, 2012 & 2018; ACOG, 2017; 
Reece-Stremtan & Marinelli, 2015). 
Gaps in Evidence 
  Marijuana’s schedule I drug classification severely curtails the amount of studies 
being conducted on its use and effects, thus creating a paucity of high quality primary human 
research to critically appraise. With the inclusion of animal studies regarding marijuana’s effect 
on lactating animals and their offspring, the evidence is still limited. This gap in the evidence 
must be acknowledged but is not likely to be bridged until the US changes marijuana’s schedule 
I status. Even with a schedule change, there are other ethical considerations to consider. True 
experimental design calls for exposure of some participants to the independent variable, in this 
case, marijuana. It would be unethical to expose breastfeeding infants to a potentially harmful 
substance. These types of ethical dilemmas are the very things an institutional review board 
seeks to prevent. According to the FDA, an institutional review board [IRB] is tasked with 
monitoring research involving human subjects and seeks to protect the rights and welfare of the 
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subjects (U.S. Food and Drug Administration, 2018), limiting the generation of evidence needed 
for recommendations. 
Professional consensus states that the breastfeeding mother should be counseled 
regarding the effects of her marijuana use while breastfeeding. This consensus provides the basis 
of this DNP project. The quality of care of breastfeeding mothers is impacted when this critical 
discussion does not occur or when critically appraised research is not included in provider 
recommendations. In order to address this quality gap, a critical review of the literature was 
completed as the basis for evidence-based healthcare provider training and implementation of 
counseling of breastfeeding mothers. The measure for this QI project will be the documentation 
that breastfeeding mothers are receiving this evidence-based counseling regarding marijuana use 
during breastfeeding.  
Conceptual Framework 
The conceptual framework for this DNP project will be Carver & Scheier’s (Carver & 
Scheier, 1982) control theory. The key tenets of control theory postulate that a discrepancy 
between current practice and a standard motivates one to change their behavior to achieve the 
standard (Mazurek Melnyk & Fineout-Overholt, 2015, p 290). The current recommendations for 
nursing mothers who use marijuana is to counsel them regarding the potential effects of THC on 
their infant and discourage marijuana use while breastfeeding or discontinue breastfeeding. 
Communicating how current practice deviates from the standard should motivate providers to 
change practice regarding their counseling and documentation of breastfeeding mothers who use 
marijuana. Currently, not providing evidence-based counseling is not the standard for the 
selected private practice clinic in Alaska. 
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When applying control theory to EBP, Mazurek Melnyk and Fineout-Overholt contend 
that there are several barriers to successful implementation (Mazurek Melnyk & Fineout-
Overholt, 2017 p. 290). Lack of knowledge and skills regarding EBP and its ability to change 
practice, lack of an EBP mentor, perceived inability to change practice and a lack of 
administrative support and possibly outright management resistance to EBP may hinder the 
successfull implementation of the project. Upper management buy-in will be crucial to the 
successful implementation of the project. Knowledge of these potential barriers will be key when 
undertaking this project to avoid any pitfalls to implementation and be cognizant of individuals 
or organizational roadblocks that would derail the project.  
Utility/Feasibility 
 This QI project is beneficial to outpatient pediatric practices for several reasons. It is cost 
efficient, requiring adaptation of but no additional EHR purchases for those with existing 
systems. Project implemented in a state where recreational marijuana has recently become legal 
underscores the need for counseling based on prevalence of marijuana use during breastfeeding.  
As with any new practice change, ease of implementation and accepting the importance of the 
practice change is imperative to successful implementation and sustainability.  
Key stakeholders for this type of project in an ambulatory care setting include the office 
manager, IT staff, administrators/decision makers in the practice and all care providers. 
Engagement of these key individuals is essential in planning, implementation and evaluation of 
the QI project. Potential barriers include lack of provider buy in and perceived lack of time 
during patient interactions. These barriers should be mitigated in order for the project to be 
successfully implemented. Engagement of stakeholders will begin during the initial planning 
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phase and individuals will be periodically updated throughout the project to assure continued 
involvement and support. 
Recommendations Summary 
After critical appraisal of the evidence and professional guidelines, there is consensus 
that all nursing mothers who use marijuana should be counseled on the potential effects of 
marijuana on their infant (Reece-Stremtan & Marinelli, 2015; AAP, 2012; ACOG, 2017; Butler, 
2017).  There remains a lack of robust evidence to guide recommendations for counseling 
regarding marijuana use in breastfeeding mothers, limiting provider confidence and ability to 
make evidence-based recommendations.  Professional guidelines have not led to a definitive 
consensus but recommended that while the benefits of breastfeeding are significant, marijuana 
use should be limited or discontinued during breastfeeding based on the potential risks to the 
infant as a result of exposure to marijuana transferred to breastmilk and ingested by the infant.  
 
Section Three: Methods 
Assess the Need for Change in Practice 
The purpose of this quality improvement project is to identify the degree to which 
breastfeeding mothers are using marijuana and to document evidence-based counseling on 
effects during breastfeeding.  We will accomplish this by (1) training pediatric health care 
providers in evidence-based recommendations to breastfeeding mothers regarding marijuana use 
and (2) establish an electronic system to facilitate provider counseling of evidence-based 
recommendations regarding marijuana use to breastfeeding mothers. We anticipate the outcome 
to be increased identification of breastfeeding mothers who use marijuana and improved 
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documentation of evidence-based counseling regarding the effects of marijuana on the 
breastfeeding dyad. The project was designed to develop an evidence-based provider training on 
marijuana use while breastfeeding, to promote provider inquiry regarding maternal marijuana use 
during breastfeeding and to improve provider documentation of evidence-based maternal 
counseling regarding marijuana use during lactation.. The protocol for the project was approved 
for expedited review by The Ohio State University Biomedical Sciences Institutional Review 
Board.  
 The Model for Evidence-Based Practice Change was utilized as the framework for the 
DNP project (Rosswurm & Larrabee, 1999).  The model begins with assessment of the 
organizational culture and need for change. This assessment should include the stakeholders and 
governing body of the organization. To initiate and sustain a clinical practice change, the entire 
organization must be ready for transformation. Assessment of the practice’s readiness for change 
was accomplished by presenting the project plan to the provider partner/owners of the practice. 
All six owners are pediatricians who currently practice in the clinic. The outpatient private 
practice site selected for the DNP quality improvement project was located in a large city in 
Alaska, one of the 30 states that has legalized recreational use of marijuana. The selected 
practice is a leader in EHR documentation and currently is an innovative research site for the 
fourth largest EHR system in the country. The practice desires to be a leader at the state and 
national level regarding EHR documentation and strives to customize their current system and 
provide streamlined yet thorough documentation of patient visits, motivating their participation 
in this project. The clinic has developed its own customized EHR templates and actively works 
to update the templates based on provider feedback. The IT team was engaged and prepared to 
support the requirements of this project. The practice mission statement states that providers 
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strive to be informative while offering patient choice, consistent with evidence-based practice 
tenets.  The project aligned with the practices’ vision and mission statements and should benefit 
all participants.  
Interventions and Outcomes  
 The problem of inconsistent provision of evidence-based counseling regarding marijuana 
use in breastfeeding mothers was based upon a paucity of current, rigorous evidence to guide 
recommendations, limiting implementation of recommended counseling in practice. Linking this 
problem to suitable interventions and outcomes is the second step of the model. The intervention 
selected to address the lack of evidence-based counseling was to conduct provider training to 
share current evidence and align approaches to counseling practices. This integrated with the 
third step which was locating the evidence and searching for clinical guidelines to steer the 
project. After review of the literature and professional guidelines, there was consensus that all 
breastfeeding mothers should be counseled regarding marijuana use while breastfeeding (Reece-
Stremtan & Marinelli, 2015; AAP, 2012 & 2018; ACOG, 2017; Butler, 2017).  
Challenges in the provision of provider counseling of breastfeeding women who use 
marijuana included the need to document inquiry into marijuana use and awareness of evidence-
based counseling for consistent and current recommendations for maternal and infant effects.  
Review of the literature generated the evidence for consistent and current approaches to maternal 
counseling. The evidence lacked consistency in findings regarding maternal and infant effects of 
maternal marijuana use.  Maternal effects include suppression of prolactin and oxytocin (Asch et 
al., 1979; Bromley et al., 1978; Mendelson et al., 1984; Murphy et al., 1998; Ranganathan et al., 
2009; Tyrey, 1988; Vilela & Giusti-Paiva, 2014), and decreased breastfeeding initiation (Crume 
et al, 2018) and shorter breastfeeding duration (Ko et al. Farr, 2015). Additionally, animal 
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studies show decrease maternal care (Asch & Smith, 1986; Bromley et al, 1978; Frischknecht et 
al.; Sieber &Waser, 1980 and Vilela & Giusti-Paiva, 2014).  The potential effects on infants, 
based on study findings, are variable based upon frequency, source and route and amount of 
maternal marijuana use.  Sedation, poor growth, reduced muscle tone and poor suckling (Liston, 
1998), lethargy, less frequent and shorter feeding (IOM, 1991), behavioral and neuroendocrine 
changes (Moreno et al, 2005; and Trezza et al, 2008) as well as anxious behavior and altered 
social functioning (Newsom & Kelly, 2008) were observed. Contradictory findings regarding 
mental and motor delays in infants at one year of age were also noted (Astley & Little, 1990 and 
Tennes et al, 1985). 
In order to share findings for evidence-based counseling of breastfeeding women who use 
marijuana, it was determined by consultation with practice stakeholders that the most effective 
way to disseminate findings and implement an office wide practice change was to conduct a 
provider training for all provider staff. The training was designed to promote provider inquiry 
regarding maternal marijuana use during breastfeeding and to improve provider documentation 
of evidence-based maternal counseling regarding marijuana use during lactation.  To facilitate 
consistent documentation of inquiry into marijuana use among breastfeeding women, a 
modification to the EHR system was implemented to prompt providers to ask breastfeeding 
mothers about their marijuana use.  When marijuana use during breastfeeding was confirmed, 
standardized patient education handouts with evidence-based recommendations were generated.  
Together, this intervention served to ease provider documentation while assuring the provision of 
evidence-based patient handouts. After provider training, the outcome of the QI project was 
analyzed by pre- and post-training chart evaluation of (1) frequency of documentation of inquiry 
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regarding marijuana use during breastfeeding and (2) provision of evidence-based education for 
a period of 3 months each, respectively. 
Design Practice Change 
Design of the practice change is the fourth step in the model. The goal of the practice 
change was to promote documentation of counseling of marijuana use in breastfeeding women.  
The timeline was as follows: 




                 3 Months                                                                                 3 Months 
A provider training session (Appendix A) was developed and delivered by the DNP 
student based upon review of the evidence. The primary focus of the training was to concisely 
review current research and recommendations and formulate an evidence-based response to 
guide providers when discussing marijuana use with breastfeeding mothers . The presentation 
began with an overview of the prevalence of marijuana use nationwide, highlighting high risk 
women and use among pregnant and postpartum mothers (ACOG, 2015; Crume et al., 2018; 
Gilchrist et al., 1996; NIDA, 2018; USDEA, 2018; Schauer et al., 2016 and “State marijuana 
laws in 2018”, 2018). The pharmacology of marijuana was reviewed and included half- life, 
routes of administration and THC concentration (Campolongo et al., 2001; Djulus et al., 2005; 
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Owens et al., 1981, and Smith et al., 1999). Time was spent reviewing the properties of 
marijuana that make it pass readily into breastmilk (Hale & Rowe, 2017 and Kruez & Axelrod, 
1973) and reviewed concentrations of THC in fore and hindmilk (Gardiner, 2001). There was a 
summary of the literature presenting the studied effects of marijuana exposure on infants and 
mothers. Recommendations from professional organizations (ACOG, AAP, ABM and DHSS) 
were outlined as well as areas of consensus and deviation (ACOG, 2017; AAP 2012 & 2018; 
Butler, 2017; and Reece-Stremtan & Marinelli, 2015). A brief summary of maternal marijuana 
use during lactation was distributed to the providers for future reference.  
Focus was then turned to EHR documentation of standardized counseling provided to 
mothers who acknowledged marijuana use while breastfeeding.  Maternal choice/preference was 
also incorporated as a tenet of counseling. Ultimately, it would be the mother who decided her 
course of action based on the evidence and guidelines provided. Incorporating the patient’s 
wishes reflected patient centered care, a standard in today’s healthcare world. Linking patient 
centeredness and evidence-based healthcare required the patient to be informed about potential 
outcomes while allowing the provider to fully appreciate patient preferences (Sambare, Uhler, & 
Bozic, 2017). 
The in-person provider training was conducted for all physician and nurse practitioner 
providers by the DNP student to provide current evidence-based counseling approaches and 
patient-centered education. The DNP student also worked closely with the office manager/IT 
manager to initiate an electronic mechanism for documentation of evidence-based counseling in 
breastfeeding women (Appendix B).   
The effectiveness of the practice change was determined by a comparison of 
documentation before and after provider training. Data collection was based on documentation at 
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the 2 week well child visits as this is a critical opportunity for breastfeeding dyad counseling. 
Data collection occurred over a six-month period, including 3 months prior to and after provider 
training. Outcomes included provider documentation for frequency of documentation of maternal 
marijuana use before and after provider training and the provision of evidence-based 
recommendations for marijuana use during breastfeeding if there was confirmation of maternal 
marijuana use.  
Implement and Evaluate Change 
After IRB approval was received, the project was implemented. Provider training 
(Appendix A) introduced evidence and educational materials for use in the counseling of 
breastfeeding mothers who use marijuana. The training summarized existing data regarding 
marijuana use while breastfeeding. Training was focused on EHR documentation and review of 
the parental handout topics. The EHR icon was created in the current electronic software utilized 
by the office. The icon added the ICD-10 code of “newborn affected by maternal marijuana use” 
(P04.9) to the infant’s chart. Providers were instructed on the process for insertion of the new 
tracking codes into the two week well visit EHR note. Under the heading of lactation marijuana 
use screening, the provider had the option to choose the following ICD 10 (P code) and/or 
procedure code (5-digit code): 
No maternal marijuana use (67825) 
Newborn affected by maternal marijuana use (P04.9) 
Newborn affected by maternal marijuana use (67810) 
Maternal Marijuana use while breastfeeding education 
 
A patient education handout was automatically generated when the provider chose the 
P04.9 code and the parent(s) were given the preprinted educational material when they checked 
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out. The educational handout, generated from the evaluation of the current literature, was written 
at a 4th grade reading level. Guidance for the writing of the patient educational material 
(Appendix B) was obtained from the CDC handout, “Simply Put” (CDC, 2009) as well as input 
by the DNP student’s advisory committee. It included the following: 
You should limit or stop using marijuana (weed, pot) while breastfeeding. 
There is no safe time to nurse your baby after using marijuana. 
Marijuana may: 
  Decrease your breastmilk supply 
  Affect your baby’s brain 
  Affect your baby’s behavior  
 
The project was implemented over a six-month period. Provider documentation of 
maternal marijuana use and related education prior to training was completed as free text, 
requiring the provider to include a narrative documenting marijuana use and counseling.  After 
training, the documentation was facilitated by the new icon in the EHR.  Data was collected 
devoid of any identifying data and stored on The Ohio State University protected research drive 
(R drive).  
 
Integrate and Maintain Practice Change 
The final step of the process was the integration and maintenance of the QI practice 
change. This step included dissemination of QI project findings to all stakeholders and 
participants. Sharing of the QI project findings also took place at a scheduled provider/manager 
meeting and ongoing reports regarding EHR icon usage will continue to be generated to assess 
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ongoing compliance and quality improvement. The project intent is to continue such counseling 
and documentation indefinitely with adaption of counseling via provider update as needed.     
 
Section Four: Findings 
Results 
Data were identified in EHR by running a report based on the ICD 10 code for a 2 week 
well visit from (Z00.111). Mothers who were formula feeding at the two week well visit were 
excluded from the report. During the 3-month pre-training period, a total of 151 participants met 
this criterion and were reviewed for any type of provider documentation regarding maternal 
marijuana use and evidence of any provider counseling to breastfeeding mothers who admitted to 
marijuana use. Documentation was reviewed for any evidence of the provider asking about 
maternal marijuana use. Among mothers who were asked about marijuana use, the 
documentation was reviewed for either a yes or no response to maternal use. If the mother 
answered affirmatively (yes), documentation of the type of provider education regarding 
marijuana use while breastfeeding was recorded. 
Provider training was conducted on October 2, 2018. Total providers included in the 
project were 11 pediatricians, 6 nurse practitioners and 1 medical resident (n=18). Following the 
provider training, a monthly chart review was conducted for a 3-month period to assess the 
documentation of counseling of marijuana use in breastfeeding women. Reports were again run 
based on an ICD 10 code search for the 2 week well child visit. Formula feeding mothers were 
excluded from data collection. A total of 203 charts were reviewed during this period. The QI 
project concluded on January 17, 2019. 
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Maternal Marijuana Use and Documentation 
 Figure 1 illustrates findings of the degree to which breastfeeding mothers were asked 
about using marijuana over the 6-month project window. An EHR query was performed 
searching for the ICD 10 code for a 2 week well child visit (Z00.111). A total of 151 charts met 
criteria (n=151). Identical EHR queries generated data for three consecutive months following 




Figure 1: The X axis illustrates data points for the 3 months prior to project intervention 










3 Months Pre Intervention 1 Month Post Intervention 2 Month Post Intervention 3 Month Post Intervention
Breastfeeding Mothers Asked about Marijuana Use
Yes No
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Prior to intervention, only 4 charts had any provider documentation for inquiry of 
maternal marijuana use (2.6%).  The percentage of breastfeeding mothers being asked about 
marijuana use at the 2-week well child visit increased post intervention. For the first month post 
intervention (n=82), 45 mothers were asked about marijuana use (54.8%). Month 2 showed a 
decrease in overall charts (n=54) with 20 mothers being asked about their marijuana use. 
(37.0%). During month 3 of the project, a total of 67 participants met inclusion criteria (n=67) 
with 34 mothers being asked (50.7%).  
Figure 2 illustrates documentation of evidenced based counseling for  mothers who use 
marijuana while breastfeeding. The same queries and inclusion criteria pertained to this portion 
of the project analysis, yielding a total of 151 participants prior to project implementation and 
203 project participants in the post training period.  These charts were reviewed for any 









Figure 2 graphically represents maternal response to marijuana use prior to provider 
training (n=4). Out of the 4 mothers who were asked, 2 responded affirmatively, 2 denied use. Of 
the two who admitted using marijuana while breastfeeding, one was advised to decrease use and 
one did not receive any type of provider counseling (50%). Documentation did not address 
maternal or infant effects of marijuana use while breastfeeding. 
 
Figure 3 
Maternal Response to Marijuana Use (n=4)
Marijuana use Yes Marijuana use No




Figure 3 is a representation of mothers who were asked about marijuana use for the 3 
months post provider training. Two mothers answered affirmatively and were given the 
standardized counseling as outlined in the provider training (100%).  
Discussion 
Returning to the purpose of the project, to identify the degree to which breastfeeding 
mothers are using marijuana and the documentation of evidenced-based counseling by the 
provider, both primary goals were addressed. The project trained pediatric health care providers 
in evidence-based recommendations to breastfeeding mothers regarding marijuana use and 
established an electronic system to facilitate provider counseling regarding marijuana use to 
breastfeeding mothers. 
Marijuana Usage Among Breastfeeding Mothers 
Data collected from pre and post provider training shed light on provider practices 
regarding mothers who breastfeed and choose to use marijuana. Prior to the training, only 2.6% 
of all breastfeeding mothers were asked about marijuana use. Month 1 post provider training 
Maternal Response to Marijuana Use (n=99)
Marijuana Use Yes Marijuana Use No
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showed an increase in documentation of maternal marijuana use to 54.8%. This was an increase 
of 52.16%.  The documentation percentage fell to 37% during month 2 of the project but 
increased to 50.7% again by month 3.  Clearly, providers were better at documenting this 
intervention when they had received evidence-based training and had access to an EHR icon that 
standardized documentation.  
The increase in documentation may also have been from their increased confidence in 
discussing marijuana use while breastfeeding due to their education during the provider training. 
Comments by providers during and after the training revealed a hesitancy to ask mothers about 
their marijuana use because they did not know what to tell parents about the effects of marijuana 
use on their infants. This lack of knowledge was mitigated by the provider training. This alone 
may have increased providers asking about maternal marijuana use.  
Initially, the decrease may have been attributed to forgetting to document maternal 
marijuana use since it had been a month since initial training. However, during month 3, the 
percentage of documentation had increased again to 50.7%.  
The time period for month 2 spanned from November 18th to December 17th. This 
period included the Thanksgiving holiday and also a 7.0 magnitude earthquake in the region. 
This earthquake was the largest of that magnitude in the area for several years. Since two other 
major holidays occurred during month 3 but did not generate a fall in documentation, it is 
possible that the earthquake alone may have influenced providers’ documentation. It is 
postulated that providers, like many other residents of Alaska close to the epicenter that day, 
were disturbed by the earthquake which affected day to day activities. As with any natural 
disaster, individuals tend to become preoccupied with their own safety and security and that of 
their families as well.  
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Provider Counseling of Mothers 
Findings regarding type of counseling breastfeeding mothers who disclosed 
marijuana use indicated only 1 of 2 women (50%) were given any counseling prior to provider 
training. This counseling only included decreasing marijuana use. For mothers who attested to 
marijuana use while breastfeeding post training, both mothers (100%) received counseling 
pertaining to all areas of marijuana use while breastfeeding. These included maternal lactation 
and infant effects of marijuana exposure while nursing.  
It also must be noted that the project occurred in a state that has fully legalized all forms 
of marijuana use and there is no legal penalty for a parent who discloses marijuana use. This may 
have been a benefit to implementing this particular project, but one must also concede that 
marijuana use, though legal in Alaska, still has a stigma associated with it and parents may not 
have wanted to disclose their use to the provider, regardless of lack of repercussions.  
Limitations 
 The project’s major limitation is based on the fact that marijuana may have a stigma 
associated with its use which may make parents hesitant to disclose their use. There are also 
legal ramifications based on state laws whereas this project may not be feasibly implemented in 
states where full legalization of marijuana has not been achieved. The real possibility of 
prosecution for use of an illegal substance or loss of custody of their infant would surely deter 
parents from disclosing marijuana use.  
Another limitation to the project is the comfort level of the provider to ask about maternal 
marijuana use. Personal bias regarding marijuana use may deter some providers from engaging 
in the discussion. This may stem from their belief that marijuana is dangerous or harmful to the 
infant and/or mother or that it has not been studied sufficiently to provide a definitive 
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recommendation to the mother. The provider may also be hesitant to ask about maternal 
marijuana use because they do not know how to respond to potential questions or how to broach 
the subject with their patients. It was hoped that the provider discussion would alleviate provider 
apprehension regarding recommendations, but the training did not specifically address how to 
ask the question initially. This was addressed during the question and answer session however by 
the DNP student by suggesting the provider combine the use of alcohol by breastfeeding mothers 
with marijuana use.  
One final limitation of this project was the low number of affirmative responses to maternal 
marijuana use. Prior to project implementation, it was discovered that 8% of Alaska nursing 
mothers reported marijuana use (Alaska Department of Health and Human Services, 2015).  
Only 4 mothers (1%) disclosed their marijuana use to their provider. It was expected that 
the opportunity for maternal teaching would have been higher during this project. 
Section Five: Recommendations and Implications for Practice 
Project Summary 
Marijuana use among breastfeeding mothers is an emerging topic among pediatric 
providers and lactation consultants worldwide. Legalization of marijuana in many states is also 
currently being debated and will likely be on state ballots throughout the United States in the 
coming years. There is also a current need for increased research on marijuana for a variety of 
uses as well as the increased study of current strains of marijuana and its increased THC content. 
Practice implications of this project continue to evolve and expand as this topic is dynamic and 
far reaching in both the United States and throughout the world.  
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Implications for Nursing Practice and to the DNP Essentials 
This project was grounded in the DNP essentials as outlined by the American Association 
of Colleges of Nursing (2009). Reflection on each of the essentials as it applies to this project 
should be addressed. 
Essential I: Scientific Underpinning 
  The entire QI project was based on current research on marijuana use while 
breastfeeding. Due to the lack of rigorous quality studies, partially due to marijuana’s level I 
DEA classification, older articles were included in the literature review. The provider training 
summarized the extensive literature review and the patient handout was created directly from 
literature-based evidence. 
Essential II: Organizational and Systems Leadership for Quality Improvement and 
Systems Thinking 
  A need for maternal screening for marijuana use and development of an evidence-
based provider training was identified by the DNP student to provider better patient care and 
documentation. A system wide change was developed and implemented and planned for wider 
dissemination in the upcoming year. 
Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice 
  The project was developed using critical appraisal skills for analyzing vast 
numbers of research articles. The entire provider training materials and patient information was 
created using results gleaned from the extensive literature query as well as ongoing literature 
searches of new studies on the topic. The DNP student was guided by an expert advisor and 
committee throughout the creation, implementation and dissemination of the project findings. 
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Essential IV: Information Systems/Technology and Patient Care Technology for the 
Improvement and Transformation of Health Care 
  Use of information technology was essential in the development of this QI 
practice change. It afforded a platform to both gain insight into current practice and provided a 
vehicle to accurately document patient data, generate educational material and continuously 
screen provider compliance with the practice change. It is hoped that this EHR change will be 
adapted to other clients of the system throughout the country. 
Essential V Health Care Policy for Advocacy in Health Care  
  The project was born out of the need for health care policy change generated by a 
statewide and national trend toward marijuana legalization. There was clearly a practice gap in 
the state created by recent marijuana legalization and current recommendations by governing 
bodies to both screen breastfeeding mothers and counsel them based on current research on the 
topic.  
Essential VI Interprofessional Collaboration for Improving Patient and Population Health 
Outcomes 
  The student collaborated with private practice and state authorities to accomplish 
this practice change. A variety of disciplines were involved to create a meaningful and 
informative training as well as providing consistent documentation and patient education. 
Without interprofessional collaboration, this project could not have been as successful nor poised 
for wider distribution to affect healthcare change to a wide population. Stakeholder engagement 
was also essential to the project. Both the practice providers/owners and IT department 
collaboration were essential to the success of the project. 
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Essential VII: Clinical Prevention and Population Health for Improving the Nation’s 
Health 
  The increasing incidence of marijuana legalization nationwide brings with it a 
change in the nation’s health. It is hard to tell the long-term repercussions of this widening 
legalization, but it is imperative that healthcare providers screen breastfeeding mothers about 
their use and educate them regarding the potential effects on their nursing infants. If there are 
long term effects on the nursing infant, this could cause a need for specialized care of these 
infants as they mature. Also, if marijuana exposure through breastmilk is found to be harmful, it 
is the provider’s duty to inform the mother and protect the child. 
Essential VIII: Advanced Nursing Practice 
  The training should enlighten and enhance the provider’s knowledge of marijuana 
use while breastfeeding as well as encourage them to have such discussions with their patients. 
Additionally, for this particular practice, iy provided exposure to the evolving role of the nurse 
practitioner and to the Doctor of Nursing practice degree. It may also inspire future practitioners 
to pursue a doctoral degree.  
Methods for Dissemination 
Dissemination of this project is planned for local, state and international groups over the 
next year. Findings of this project will begin at the office where the QI project was implemented. 
It is planned that the entire project will be presented at the next provider meeting as well as a full 
written report to be distributed to the practice partner/owners as well as the IT manager. It will be 
recommended that this project be continued indefinitely with the DNP student continuing to 
monitor documentation as well as updating provider training as needed with any new published 
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data. This will be accomplished by periodic literature searches as well as provider training for 
any new provider employees.  
Statewide dissemination of this project is being planned at the Alaska State Breastfeeding 
Coalition annual meeting scheduled in April of 2020. This is an annual conference for anyone 
who provides breastfeeding support to mothers. It is typically attended by IBCLCs, dietitians, 
providers (MD, DO, ND, NP, CNM) and the lay public that cares for nursing mothers and 
infants. The DNP student will continue to be in contact with the Alaska State Department of 
Health and Social Services medical director to facilitate dissemination of information to other 
pediatric providers in the state. 
National and international dissemination will be achieved by publishing this project on 
the Ohio State University database as well as submitting an abstract to appropriate medical 
publications. Additionally, an abstract of these findings was submitted and accepted and the 
DNP student will be presenting at the annual conference of International Board Certified 
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Prevalence of Marijuana Use 
   Most commonly used illicit drug in the United States (National Institute on 
Drug Abuse [NIDA], 2018) 
 Legal in 30 states and District of Columbia (State marijuana laws in 2018, 
2018) 
 6% of pregnant women and 5% continue marijuana use while 
breastfeeding (Crume et al., 2018) 
   15-18 % of socioeconomically disadvantaged women (ACOG, 2015) 
 Adolescent pregnancy- use rose in first 6 months postpartum (Gilchrist, 







Marijuana Use: A Provider 
Counseling Guide 
Jennifer McKinnon, MSN, FNP, IBCLC 
Pharmacology of Marijuana 
   Delta-9-tetrahydrocannabinol (THC) is the active component in marijuana 
   THC is an agonist of cannabinoid (CB) receptors (Fride, 2001) 
 CB receptors make up endocannabinoid system which are active by 19th 
week of gestation (Campolongo, Trezza, Ratano et al, 2001) 
 essential for attention, cognition, memory, emotion, movement, immune system 
(Jutras-Aswas, DiNieri, Harkany et al, 2009) 
 THC action on anterior pituitary 
 promotes corticotropin secretion 
 Inhibits secretion of gonadotropin, thyroid-stimulating hormone, prolactin and 
growth hormone (Murphy, Munoz, Adrian et al, 1998) 
 
Pharmacology of Marijuana 
   Half Life (Smith-Kielland, Skuterud & Morland, 1999) 
 1.3 days for one marijuana cigarette 
  5-13 days for heavy user 
   THC Routes 
 Smoking 
 plasma peak in 1-2 hours (Hollister et al., 1981) 
 0.8% of mother’s dose of one marijuana joint transfers to infant (Djulus, Moretti & Koren, 
2005) 
 Oral 
 Plasma peak in 2-4 hours (Hollister et al., 1981) 
 Reduced bioavailability by 4-12% (Owens, Reisner, & Perez-Reyes, 1981) 
 THC in marijuana has risen from 3.96% to 11.84% from 1995 to 2014 (ElSohly 
et al 2010) 
Pharmacology of Marijuana 
   Low molecular weight (314 g/mol) (Hale &Rowe, 2017) 
   High Volume of Distribution (4-19 L/kg) (Hale &Rowe, 2017) 
   Long Elimination half-life (25-57 hours) (Kruez &Axelrod, 1973) 
 Lipophilic- should readily transfer into breastmilk (Hale &Rowe, 2017 p. 
e1164-172) 
 Foremilk (milk produced in first 3 minute of feeding/pumping) has less fat  
 Hindmilk (remainder of milk produced during feeding/pumping) 
 Increased amounts of THC (Gardiner, 2001) 
Effects of Marijuana Exposure on 
Infants 
Human Studies 
 Sedation, poor growth reduced muscle 
tone, poor suckling (Liston, 1998) 
 Lethargy, less frequent and shorter 
feedings (Institute of Medicine, 1991)  
 No correlation between marijuana 
exposure and infant growth and 
development at 1 year of age (Tennes et 
al, 1985) 
 Impaired motor function at 1 year of age 
(Astley & Little, 1990) 
  No detectable mental delays at 1 yr 
(Astley & Little, 1990) 
Animal Studies 
 Behavioral and neuroendocrine changes 
(Moreno et al, 2005; Navarro, 2005; 
Trezza et al, 2008) 
 Anxious behavior and altered social 
functioning (Newsom& Kelly, 2008) 
Maternal Effects of Marijuana 
Human Studies 
 Suppresses prolactin production 
(Murphy, Munoz, Adrian & Villanua, 
1998; Mendelson, Ellingboe & Mello 
1984; Ranganathan et al., 2009) 
 Decreased oxytocin release (Tyrey, 
1988) 
  Decreased breastfeeding initiation 
(Crume et al, 2018) 
 Shorter breastfeeding duration (Ko, 
Farr, Tong, Creanga & Callaghan, 
2015) 
Animal Studies 
  Decreased oxytocin and prolactin 
release (Tyrey & Murphy, 1988; Vilela & 
Giusti-Paiva, 2014; Bromley, Rabii, 
Gordon & Zimmerman, 1978; Asch, Smith, 
Siler-Khodr & Pauerstein, 1979) 
 Decreased care of offspring (Bromley et 
al, 1978) 
 Decreased licking, retrieval and carry of 
pups (Vilela & Giusti-Paiva, 2014) 
 Decreased maternal nonsocial activities  
(Frischknecht, Sieber & Waser, 1980) 
 Maternal depression and lethargy (Asch 
& Smith, 1986) 
 
Recommendations for Marijuana Use 
While Breastfeeding 
 
 AAP- “Street drugs such as PCP, cocaine, and cannabis can be detected in human milk, 
and their use by breastfeeding and their use by breastfeeding mothers is of concerns, 
particularly with regard to the infant’s long-term neurobehavioral development and thus 
are contraindicated.” (Garry et al., 2009)  
 AAP-”Present data are insufficient to assess the effects of exposure of infants to maternal 
marijuana use during breastfeeding. As a result, maternal marijuana use while 
breastfeeding is discouraged”. (AAP, 2018) 
 ACOG- “There are insufficient data to evaluate the effects of marijuana use on infants 
during lactation and breastfeeding, and in the absence of such data, marijuana use is 
discouraged.” (ACOG, 2017) 
 ABM- “Breastfeeding mothers should be counseled to reduce or eliminate their use of 
marijuana to avoid exposing their infants to this substance and advised of the possible 
long-term neurobehavioral effect from continued use.” (Reece-Stremtan & Marinelli, 2015) 
 ADHSS- “continue to breastfeed while making every effort to reduce the amount of 
marijuana consumed, whether smoked, vaped or eaten” (Butler, 2017)  
 






Summary of Maternal Marijuana Use 
During Lactation 
 
 About 1 % of mother's marijuana cigarette transfers to infant. (Djulus, Moretti & 
Koren, 2005). 
 Approximately 10-27% of THC reaches infant(Pertwee, 2005; Castle& Murray, 
2004), (McBurney, Bobbie & Sepp, 1986) 
 There is a 12-14% decrease in the infant’s THC dose if using edible marijuana 
(Owens, Reisner, & Perez-Reyes, 1981) 
 Marijuana use may cause poor infant growth and development, impair motor 
development at 1 yr of age, decrease infant muscle tone, cause a poor suck 
and lethargy and decrease breastfeeding frequency and duration. Animal 
studies also show increased maternal anxiety and altered social functioning. 
 Marijuana suppresses prolactin and oxytocin release and decreases 
breastfeeding initiation and duration rates. In animal studies, marijuana causes 
decreased maternal care of offspring, decreased maternal nonsocial behavior 
and is linked to maternal depression and lethargy. 
Handout to Parents 
   You should limit or stop using marijuana (weed, pot) while breastfeeding. 
   There is no safe time to nurse your baby after using marijuana. 
   Marijuana may: 
    Decrease your breastmilk supply 
    Affect your baby’s brain 
    Affect your baby’s behavior 
Questions? 
References 
 American Academy of Pediatrics. (2012). Breastfeeding and the use of human milk. Pediatrics, 129(3), 598-601. doi:10.1542/peds.2011-3552 
 American Academy of Pediatrics. (2018). Marijuana use during pregnancy and breastfeeding: Implications for neonatal and childhood outcomes. Pediatrics, 142(3), 10.1542/peds.2018-1889. 






Asch, R. H., Smith, C. G., Siler-Khodr, T. M., & Pauerstein, C. J. (1979). Acute decreases in serum prolactin concentrations caused by delta 9-tetrahydrocannabinol in nonhuman primates. Fertility 
and Sterility, 32(5), 571-575. doi:S0015-0282(16)44362-1 [pii] 
 








Bromley, B. L., Rabii, J., Gordon, J. H., & Zimmerman, E. (1978). Delta-9-tetrahydrocannabinol inhibition of suckling-induced prolactin release in the lactating rat. Endocrine Research 
Communications, 5(4), 271-278.  
 
Butler, J. C. (2017). In Alaskan health care providers (Ed.), Breastfeeding mothers reporting marijuana use are encouraged to continue breastfeeding  
 






Campolongo, P., Trezza, V., Ratano, P., Palmery, M., & Cuomo, V. (2011). Developmental consequences of perinatal cannabis exposure: Behavioral and neuroendocrine effects in adult 
rodents. Psychopharmacology, 214(1), 5-15. doi:10.1007/s00213-010-1892-x [doi] 
 






Crume, T. L., Juhl, A. L., Brooks-Russell, A., Hall, K. E., Wymore, E., & Borgelt, L. M. (2018). Cannabis use during the perinatal period in a state with legal ized recreational and medical marijuana: The 
association between maternal characteristics, breastfeeding patterns, and neonatal outcomes. The Journal of Pediatrics, 197, 90-96. doi:S0022-3476(18)30181-1 [pii] 
 













ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016). Changes in cannabis potency over the last 2 decades (1995-2014): Analysis of current data in the united 
states. Biological Psychiatry, 79(7), 613-619.  doi:10.1016/j.biopsych.2016.01.004  [doi] 
 
 
Fride, E., Ginzburg, Y., Breuer, A., Bisogno, T., Di Marzo, V., & Mechoulam, R. (2001). Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. European Journal of 
Pharmacology,  419(2-3),  207-214.  doi:S0014-2999(01)00953-0 [pii] 
Frischknecht, H. R., Sieber, B., & Waser, P. G. (1980). Behavioral effects of hashish in mice. II. nursing behavior and development of the sucklings. Psychopharmacology, 70(2), 155-161. 
Gardiner, S. (2001). Drug safety in lactation. information for health professionals. Retrieved from http://www.medsafe.govt.nz/Profs/PUarticles/lactation.htm 
 Garry, A., Rigourd, V., Amirouche, A., Fauroux, V., Aubry, S., & Serreau, R. (2009). Cannabis and breastfeeding. Journal of Toxicology, 2009, 596149. doi:10.1155/2009/596149 [doi] 
References 
 Gilchrist, L. D., Hussey, J. M., Gillmore, M. R., Lohr, M. J., & Morrison, D. M. (1996). Drug use among adolescent mothers: Prepregnancy to 18 months postpartum. The Journal of Adolescent Health : 




Hale, T. W., & Rowe, H. (2017). Medications and mothers' MIlk. New York: Springer Publishing. 
 
Hollister, L. E., Gillespie, H. K., Ohlsson, A., Lindgren, J. E., Wahlen, A., & Agurell , S. (1981). Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? Journal of 




Institute of Medicine. (1991). Nutrition during lactation. Washington, DC: The National Academies Press.10.17226/1577 Retrieved from https://www.nap.edu/catalog/1577/nutrition-during-lactation 
 
Jutras-Aswad, D., DiNieri, J. A., Harkany, T., & Hurd, Y. L. (2009). Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. European 
Archives of Psychiatry and Clinical Neuroscience, 259(7), 395-412. doi:10.1007/s00406-009-0027-z [doi] 
 Ko, J. Y., Farr, S. L., Tong, V. T., Creanga, A. A., & Callaghan, W. M. (2015). Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. American 












Kreuz, D. S., & Axelrod, J. (1973). Delta-9-tetrahydrocannabinol: Localization in body fat. Science (New York, N.Y.), 179(4071), 391-393. 
 
 
Liston, J. (1998). Breastfeeding and the use of recreational drugs -- alcohol, caffeine, nicotine and marijuana. Breastfeeding Review, 6(2), 27-30.  
 
 
McBurney, L. J., Bobbie, B. A., & Sepp, L. A. (1986). GC/MS and EMIT analyses for delta 9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. Journal of Analytical 
Toxicology, 10(2), 56-64. 
 
 
Mendelson, J. H., Ellingboe, J., & Mello, N. K. (1984). Acute effects of natural and synthetic cannabis compounds on prolactin levels in human males. Pharmacology, Biochemistry, and Behavior, 
20(1), 103-106. 0091-3057(84)90109-6 [pii] 
 Moreno, M., Escuredo, L., Munoz, R., Rodriguez de Fonseca, F., & Navarro, M. (2005). Long-term behavioural and neuroendocrine effects of perinatal activation or blockade of CB1 cannabinoid 






Murphy, L. L., Munoz, R. M., Adrian, B. A., & Villanua, M. A. (1998). Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiology of Disease, 5(6 Pt B), 
432-446. doi:S0969996198902248 [pii] 
 






Newsom, R. J., & Kelly, S. J. (2008). Perinatal delta-9-tetrahydrocannabinol exposure disrupts social and open field behavior in adult male rats. Neurotoxicology and Teratology, 30(3), 213-219. 
doi:10.1016/j.ntt.2007.12.007  [doi] 
 
 
Owens, S. M., McBay, A. J., Reisner, H. M., & Perez-Reyes, M. (1981). 125I radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation 




 Pertwee, R. G. (2005). Pharmacological actions of cannabinoids. Handbook of Experimental 
Pharmacology, (168)(168), 1-51. 
 Reece-Stremtan, S., & Marinelli, K. A. (2015). ABM clinical protocol #21: Guidelines for 
breastfeeding and substance use or substance use disorder, revised 2015. Breastfeeding 
Medicine, 10, 135-141. doi:10.1089/bfm.2015.9992 
   State marijuana laws in 2018. (March, 2018). Governing, July 25, 2018. 
 Smith-Kielland, A., Skuterud, B., & Morland, J. (1999). Urinary excretion of 11-nor-9-carboxy-delta9- 
tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. Journal of 
Analytical Toxicology, 23(5), 323-332. 
 Tennes, K., Avitable, N., Blackard, C., Boyles, C., Hassoun, B., Holmes, L., & Kreye, M. (1985). 
Marijuana: Prenatal and postnatal exposure in the human. NIDA Research Monograph, 59, 48-60. 
 Tyrey, L., & Murphy, L. L. (1988). Inhibition of suckling-induced milk ejections in the lactating rat by 
delta 9-tetrahydrocannabinol. Endocrinology, 123(1), 469-472. doi:10.1210/endo-123-1-469 [doi] 
 Vilela, F. C., & Giusti-Paiva, A. (2014). Cannabinoid receptor agonist disrupts behavioral and 















Citation Design/Method Sample /Setting 
 
Major Variables 



































2. Adverse effect of 
MJ on pregnancy, 
neonate, infant, child 
and adolescent 
3. Mechanisms used 
to explain underlying 
effects on the 
developing fetus 
4. Linkages of the 
endocannabinoid 
system to other 
neurotransmitter 
systems 
5. Issues for the 
clinician 









N/A N/A Specific to MJ use while 
breastfeeding: 
1. THC is 99% protein bound, 
lipid soluble and has molecular 
weight of 314 which allows 
transfer into milk 
2. Effect of MJ on breastfed 
infant: cited Tennes, Astley 
and Little article (individually 
reviewed later in this table) 
3. Recommendations: 
encourage mother to breastfeed 
while strongly encouraging 
mom to abstain from using MJ 
as well as alcohol, tobacco and 
other drugs as well as effects 




mothers who use 
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N/A Reviews of: 
1.epidemiology of breastfeeding 
rates 
2.Infant outcomes of breastfeeding 
(methodologic issues, 
respiratory tract 
infections and otitis 
media, GI tract 
infections, necrotizing 
enterocolitis, sudden 
infant death syndrome 
and infant mortality, 
allergic disease, celiac 
disease, inflammatory 






3. Preterm infants 
4. Maternal outcomes 
5. Economic Benefits 




8. Maternal diet 
9. Maternal medications 
10. Hospital routines (pacifier use, 
vitamins and mineral 
supplements) 
11. Growth 
12. Role of the pediatrician 
13. Business case for breastfeeding 




states MJ use by 
breastfeeding 
mothers is of 
concern, 
particularly with 














body that is 
frequently 
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body that is 
frequently cited 
















for marijuana use in 
breastfeeding 
women 
N/A Women reporting 
marijuana use should 
be counseled 
regarding potential 
adverse effects.  
Women who are 
pregnant or 
contemplating 








available for review 
to evaluate effects of 
MJ on infants during 
lactation 
In absence of 
sufficient published 
data to evaluate the 
effects of MJ use on 
infants during 
lactation and 










body that is 
frequently cited 
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Pre and Post 
Test Design 
 
Female rhesus monkeys 
receiving THC 2.5mg/kg 
during gestation from 
pregnancy diagnosis to 
day 155 (group 1, n=5), 
gestation day 55-109 
(group 2, n=5), gestation 
day 110-155 (group 3, 
n=5) with corresponding 
control groups receiving 
vehicle (n=5) in each 
group. 
Postnatal treatment of 
THC 2.5 mg/kg during 
lactation (experimental 





















placenta at term 






life of THC about 
2 hrs 
Long milk half-
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Asch, R.H., Smith, 
C.G., Siler-Khodr, 
T.M., Pauerstein, 
C.J. (1979). Acute 
decreases in serum 
prolactin 
concentrations 






















or THC and 










THC and to 
evaluate the 
possible site 













of TRH with 
































analysis to assess 
sample size 
Results may not 
be transferrable 
to human milk 
and breastfeeding 
infant 
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infant gross motor 
coordination and 




(MDI) from the 








Number of days 




Maternal age, height, 
race, income level, 
education, marital 
status, pregnancy 
history and weight 
gain, tobacco, coffee, 
alcohol and 
psychoactive drug 
use during pregnancy 
and lactation and 
marijuana use during 
pregnancy 
 
Paternal alcohol and 




3. Infant gestational 




between infant MJ 
exposure via 
breastmilk and 
infant motor and 
mental 
development at one 





MJ use and effect 





between MJ using 































than ½ of 
days in a 
period) 
affected 












associated with a 
























effect on PDI 
score. 
Did not follow 
infants past 
one year of 
age 
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samples (50 new 







reported MJ use at 






THC (ng/ml) and 
cannabidiol 
(ng/ml) reported in 
hours since last 
maternal use 
Measured the 
amount of THC 





















Most women in 
sample (88%) 
reported at least 







hour between last 
MJ exposure and 
milk sample 
collection caused a 




(unlogged is 3%/hr) 
Longest duration 
between last use of 
MJ and measurable 
delta 9-Thc was 





of MJ using 
mothers and 
lasted up to 6 
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5 (4), 271-278. 
 
Experimental 
Pre and Post 
Test Design 










IV THC (1.25 or 
4 mg/kg) or 
vehicle and then 
blood samples 
drawn 30,60, and 
120 min after 
dose of THC 
Primary:  




































lack of care 













No power analysis 
to assess sample 
size 
Animal study may 
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To examine the 
risks associated 
with alcohol and 









use in lactation 
N/A No association 
between maternal MJ 





vary, 44% depend on 
severity, 41% state 
benefits outweigh 
risks, 15% recommend 
stopping breastfeeding 
if mom using MJ 
 
Harm to infant 
exposed to MJ is 
prenatally. No clear 
risk associated with 
MJ during lactation. 
Breastfeeding mothers 
should be advised to 


























Small review of 
4 articles 
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who use MJ to 
continue breastfeeding 
N/A N/A Continue to breastfeed while 
making effort to 
reduce amount of 
MJ consumed, 
whether smoked, 
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worth to practice 
Campolongo, P., 
Treeza, V., Ratano, 
P., Palmery, M., & 






effects in adult 
rodents. 
Psychopharmacology. 
214 (1). 5-15. 
Literature 
Review 
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Critical worth to 
practice 
Chao, F.C., Green, 
D.E., Forrest, I.S., et 










15 (2), 303-317. 
Quasi 
Experimental 
Pre and Post 
Test design 
Lactating squirrel 
monkeys (n=11) and 
their young (3-4-
month-old) infants 
(n=6) received 2 
mg/kg THC orally 2 
times a week (n=6) 
or 5 times a week 
(n=5) followed by 2 
doses of 14C-THC 
(tracer) 




maternal and infant 
urine and feces 














milk, urine and 
feces  
















amount of THC 
in milk (0.19%), 




0.19% of labeled 

























No power analysis 
to assess sample 
size 
Possible species 
variation in THC 
content in milk. 
Animal study may 
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data to measure 
prenatal and 
postnatal MJ use 
(n=3207) 
Exclusions: 
nonresidents, out of 
state births, adopted 
out infants, multiple 
births (4 or more), 
maternal age < 15 
yrs 
MJ use pre (3 
months prior to 
pregnancy, first 3 
months of 
pregnancy and last 








MJ use  
Association of 











prenatal MJ use 
(P<0.02) 
Prenatal and 































prenatal MJ use 
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1. Formation of breast 
milk 
2. Mechanism of drug 
transfer into breast 
milk 
3. Factors associated 










4. Methods of 
estimating infant drug 
exposure (milk-to-
plasma ratio) 
5. Concentration of 







in the formation and 
transfer of licit 
(alcohol) and illicit 
drugs (methadone, 
MJ, cocaine, and 
heroin) into 
breastmilk. 
 Review breastfeeding 
recommendations 
N/A MJ Pka 10.6 , 
molecular wt 
314.46, lipid 
soluable MJ 97% 
bound to albumin 
Foremilk (first 3 
min of 
pumping/nursing) 




to heavy THC users 
Possible neurodev’t 
delay at 1 yr 
 
 






use should be 
evaluated on 











review of MJ  
 
Limitation: 
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Critical worth to 
practice 
Frischknecht, H.R., 
Sieber, B., Waser, 
P.G. (1980). 
Behavioral effects of 
hashish in mice. II. 
Nursing behavior and 






Pre and Post 
Test Design 
Newborn mice (n=8) 
with a body wt of 1.4 
g along with both 
parents were gavage 
fed 20 mg THC/kg or 
control of 2ml olive 
oil/kg on days 
1,3,6,8,10,13,15,17 
and 20.  
Parent nursing 
behaviors tested 1.5-
2h after 2nd and 5th 
treatment on days 3 
and 10. 
Spontaneous pup 
behavior noted on day 
21. 
Pups were weaned, 
and mothers separated 
from pups until they 
gave birth to second 
litter. Those pups were 
then weighed and days 
































care level after 
5th dose of 
THC on day 10 
postpartum. 






lower (P 0.05) 
at ages 6 and 





given THC had 
decreased 
Locomotion 
(P 0.1) and 
decreased 



































No power analysis 
to assess sample 
size 
Animal effects 
may not translate 
into human 
lactation 
Age of study 
 
Clinically feasible 
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V., Aubry, S., 














Review of  
1. Definition and  
epidemiology of MJ use 
2. Pharmacology data  
and side effects of MJ 
3. MJ and breastfeeding 
4.Polyintoxications 
To assess if MJ 
could be used 
during 
breastfeeding 
N/A Clinical and 
pharmacokinetic data 
indicated that MJ use is 
dangerous during 
breastfeeding for the 
child. 
Mothers who 










differences in two 
studies of effects 




Small number of 
studies reviewed 
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1. incidence of 
use 






4. Effects in 
women 


















N/A Heavy MJ use (> 5 
joints/week) may 
cause difficulty 
with reasoning and 
attention in 
breastfed infants 
Discourage MJ use but 
encourage breastfeeding 
Mandatory reporting of 
MJ use during 
pregnancy and punitive 
measures during 
pregnancy or breast-
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19 mg THC) 
 
IV MJ  
(5 mg THC) 
 
Oral MJ 









THC to self-ratings 





THC (ng/ml)  
 
 











smoked or IV 
route (P, 0.01) 
Oral ingestion of 
THC slower than 
smoked or injected 
route. 




THC and “high” 
Oral THC “high” 











of routes of 
administration on 





Results based on 
honest word of 
participants 
No power analysis 
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4. Prevalence of use 
in pregnancy 
5. Detecting use in 
pregnancy 
















who use cannabis 
in pregnancy on 
the potential 
effects of 
cannabis use on 
their unborn baby 
and future child 
development 
 
N/A See next 
page 
Advise women to stop using 
marijuana or 
decrease use while 
breastfeeding 
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Jaques con’t      Susceptibility to adolescent cannabis user 
may be influenced by heredity 
5% UK pregnant women use cannabis 
Use detected early in pregnancy by maternal 
and newborn toxicology, maternal hair 
samples, meconium testing, neonatal urine 
testing, questioning mother 
In utero cannabis exposure= increased risk of 
prematurity, growth restriction in mid to late 
pregnancy, low birthweight, smaller head 
circumference 
In utero cannabis exposure may impair long-
term growth and neurodev’t, impair visual 
memory, learning problems, impulse control 
problems, increased depressive symptoms, 
attention problems, increased risk of 
delinquency 
Unknown effects of medical vs recreational 
use 
of cannabis during pregnancy 
Cannabis and metabolites pass into breast 
milk in variable concentrations depending on 
maternal ingestion 
THC inhibits gonadotropin, prolactin, growth 
hormone and thyroid-stimulating hormone 
release and stimulated corticotropin release 
No safe threshold limits for cannabis use in 
pregnancy and post natally- advise moms to 
limit or stop using cannabis 
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2. Impact of 
cannabinoid 





















in pregnancy and 
early life 
N/A Endocannabinoid 
system impacts CNS 
patterning by 
modulating cell fate 
decisions in neural 
progenitor cells and 
also influences 
migration, survival 
and differentiation of 
committed neurons 
Endocannabinoid 






















Age of study 
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or telephonic) from 2-9 









Correlated of MJ use 
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worth to practice 
Kreuz, D.S., Axelrod, 
J. (1973). Delta-9-
tetrahydrocannabinol: 
Localization in body 








SQ with 14 ml 
of 1 mg/ml 
THC after 
1,3,6,9, or 13 
doses.     
Brain, lung, 
liver and 





and retention of 






THC in fat than 


















Poor description of 
study design and 
methods 
No power analysis 
to assess sample 
size 
Age of study 
 
Clinically feasible 
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Findings Conclusion Level of 
Evidence 
Quality of Evidence: 




































N/A Heavy MJ use 
showed 8x 
accumulation of 











be encouraged to 










research and AAP 
recommendation on 




Did not define “heavy” 
MJ use 
Gives opinion that 
maternal MJ use can 
distort her reality and 





Clinically feasible to 
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O., Gomez, A., 
Friguls, B., 
Pellegrinia, M., 






















MS-MS) was a 
reliable method to 
quantify amount of 
MJ in breastmilk 
Development and 
validation of LC-MS-
MS method for 
accurately measuring 





human breast milk. 
Applied method to 
screen samples from 
milk bank and 











was at least 0.99 
LC-MS-MS 
is an accurate 
tool to 
measure MJ 
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cigarette with 1.83% 
THC or placebo. 
Collected blood 
samples at specific 
intervals and plasma 
prolactin levels 
during luteal and 






































No control group 
No power analysis 
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1. MJ use 
during 
pregnancy 
2. MJ and 
breastfeeding 
3. MJ and 
epigenetic 
modifications 
4. MJ and 
public health 
agencies 
5. MJ and 
parenting skills 
 
Reviewed MJ use 




N/A Summarized ABM 
recommendations: 
1. Counsel mothers 
who admit to MJ use 
2. Counsel mothers 
with positive urine 
THC screen 
3. Counsel on benefits 
of breastfeeding vs 
potential risk of TCH 
on developing infant 
4. Lack of long term 




discourage MJ use due 
to lack of evidence. 
AAP recommendation 
that women using MJ 



















and lactation MJ 
exposure articles 
reviewed- difficult 
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MJ and fetal growth 
studies (n=20) 
MJ and preterm 
birth studies (n=3) 

















6. MJ and 
breastfeeding 
Provide practicing 






who use marijuana 
during pregnancy 
















effects on early 
neurodevelopment 
Provide counseling 
but do not 
withdraw lactation 
support 




effects on early 
neurodevelopment 
Provide counseling 
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dose of THC 
(0.1, 0.5, or 
2 mg/kg) or 
vehicle 
(n=17-24) 
(0.1 mL of 
sesame oil) 
 








and prolactin levels 
 
Extend previous 
results of on 
perinatal THC 
psychomotor 
































at lower doses 
but increase 


























No control group 
No power analysis 
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Findings Conclusion Level of 
Evidence 
Quality of Evidence: 











































































and to evaluate the 
risks of exposing 
infants to this 
medication in 
breastmilk 
PRISMA Cannabinoid (CB) 
receptors present by 





immune system in 
adults. 
THC in MJ risen 
(1995-2014) from 
3.96% +/- 1.82% to 
11.84 +/- 6.66% 
for mother and child 
Conflicting data 
exists. 





women in cities use. 












































it is impossible to make 
well-informed decision 
and that conservative 
approach is suggested 
however, then states 
that it is ultimately the 
mother’s decision 
 
Clinically feasible to 
include in provider 
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worth to practice 
Murphy, L.L., 
Munoz, R.M., 

































effects on prolactin 
secretion 






effects on other 
hormone  
 
Effects of cannabinoids 
on neuroendocrine 
regulation of the 
gonadotropins, prolactin, 
stress hormones, growth 
hormone and thyroid 
hormones 
 Role of cannabinoid 
receptors in the 
neuroendocrine 
regulation of hormone 
secretion. 

















Strength:  Valid 





Age of review 
 
Clinically feasible to 
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worth to practice 
Newsom, R.J., 
Kelly, S.J. (2008). 




social and open field 










female rats and 
their male 
offspring.  
Rats received 2 
mg/kg SQ 
THC or vehicle 
twice daily 
from gestation 
thru day 22 
and postnatally 























male rats  
Effects on 
offspring due to 
THC exposure 
across the period 
equivalent to all 





of the mean for 
each regimen 
at gestational 





day 1 to 22. 
Offspring 
weighed daily 
from day of 
live 2, 10, 21, 
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worth to practice 
Perez-Reyes, M., 
Wall, M.E., (1982). 
Presence of delta 9 
tetrahydrocannabinol 
in human milk. New 











MJ once per day 
for 7 months 
Mother2- 
smoked MJ 7 










presence in milk 
of lactation 
mother and its 









of MJ in 
breastmilk 



















Small Sample size 
Unable to replicate 
results 
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Braley, G., Pittman, 
B., Cooper, T., Perry, 
E., Krystal, J., and 
D’Souza, D.C. 
(2009). The effects of 
cannabinoids on 
serum cortisol and 







IV doses of delta 
9 THC (0.0357, 
0.0286 or 0.0714 
mg/kg) or 
placebo for both 
















Tested two previous 
hypotheses: 
1. THC produced 
dose-related 
increased in plasma 
cortisol levels and 
decrease in plasma 
prolactin levels 
2. Frequent MJ 
users showed 
altered baseline 
levels of cortisol 
and prolactin and 
blunted THC -
induced changes of 





























































 MARIJUANA AND BREASTFEEDING  
 
91 
Citation Design/Method Sample /Setting 
 
Major Variables 













































substance use or 
substance use 




mothers should be 
counseled to 
reduce or 








should be counseled to 
reduce or eliminate their 
use of marijuana to 
avoid exposing their 
infants to this substance 
and advised of the 
possible long-term 
neurobehavioral effects 
from continued use. 
Data not strong enough 
to recommend not 
breastfeeding with any 




recommendation s sole 
on legality of MJ since 
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modes of current 
























of MJ most 
prevalent in US 
adults. 













US adults only 
(18 yrs and 
older) 
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worth to practice 
Smith-Kielland, A., 
Skuterud, B., & 
Morland, J. (1999). 































of THC and the 
ration of 
THC/creatinine 
ratios in known 
drug users 
XY scatter 








life 1.3 days 
for frequent 









after exposure in 
infrequent users 
and 17,22 and 27 














use, unable to 
calculate THC dose 
Unsure when MJ 
exposure took 
place 
No mention of IRB 
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Effects of MJ 
exposure on fetal 
growth and 
development at 








At 1 yr of age: 
Bayley Infant Scale 








similar among both 
groups. 
Developmental 
measures did not 
differ 




Increased use of 
pain meds in labor 






Increased use of 
alcohol and MJ but 





No difference in 
growth and 
development at 
one year of age 
No difference in 










at MJ exposure 
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Carratu. M., Gaetani, 
S., Cuomo, V. (2008). 
Effects of perinatal 
exposure to delta-9-
tetrahydrocannabinol 
on the emotional 
reactivity of the 
offspring: A 
longitudinal 


















day 15 to 
postnatal 


































With 5 mg/kg THC, 
male offspring had 
decreased play (P< 






Moderate doses of 


















of participant rats 
No power 
analysis to assess 
sample size 
Age of study 
 
Clinically feasible 
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worth to practice 




milk ejections in the 









































THC group had 
longer delay 
before initial 




























No power analysis 
to assess sample 
size 
Animal study-may 
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Findings Conclusion Level of 
Evidence 
Quality of Evidence: 
























for marijuana and 
breastfeeding 
PRISMA THC is excreted 
into breastmilk in 
small quantities. 
THC is very fat 
soluble and 
persistent in body 
fat of users. 
THC slowly 
released over days 
or weeks.  
THC estimated 
daily intake for 
infant was 8 
mcg/kg or 2.5% of 
weight-adjusted 
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1. Cannabis use should 
be minimized or 
avoided, may impair 
parental judgement and 
child care abilities. 
2. Cannabis should not 
be smoked by anyone in 
the vicinity of infants 
due to secondhand 
exposure.  
3. Encourage mothers 
who use cannabis to 
continue to breastfeed 
and reduce or abstain 
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N/A Reviews of: 
1.epidemiology of breastfeeding 
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2.Infant outcomes of breastfeeding 
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enterocolitis, sudden 
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3. Preterm infants 
4. Maternal outcomes 
5. Economic Benefits 




8. Maternal diet 
9. Maternal medications 
10. Hospital routines (pacifier use, 
vitamins and mineral 
supplements) 
11. Growth 
12. Role of the pediatrician 
13. Business case for breastfeeding 
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Level IV Level V 
1    X  
2    X  
3    X  
4  X    
5  X    
6   X   
7   X   
8   X   
9     X 
10     X 
11     X 
12  X    
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13  X    
14     X 
15   X   
16     X 
17     X 
18   X   
19     X 
20     X 
21     X 
22   X   
23     X 
24 X     
25  X    
26     X 
27 X     
28  X    
29 X     
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30     X 
31 X     
32   X   
33 X     
34    X  
35   X   
36   X   
37   X   
38   X   
39 X     
40 X     
41 X     
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Legend of Levels of Evidence 
Level I 
Experimental study, randomized controlled trial (RCT) 
Systematic review of RCTs, with or without meta-analysis 
Level II 
 Quasi-experimental study 
 Systematic review of a combination of RCTs and quasi-experimental, or quasi-experimental studies only, with or without 
meta-analysis 
Level III 
 Non-experimental study 
 Systematic review of a combination of RCTs and quasi-experimental, or non-experimental, or non-experimental studies only, 
with or without meta-analysis. 
 Qualitative study or systematic review, with or without meta-analysis 
Level IV 
 Opinion of respected authorities and/or nationally recognized expert committees/consensus panels based on scientific 
evidence. 
  Includes: clinical practice guidelines and consensus panels 
Level V 
 Based on experimental and non-research evidence. 
  Includes: literature reviews, quality improvement, program or financial evaluation, case reports, opinion of nationally 
recognized expert(s) based on experiential evidence 
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